List view / Grid view
23 September 2015 | By Victoria White
A Phase IIIb/IV study demonstrated that viral suppression was non-inferior for patients switching to once-daily Triumeq from an antiretroviral therapy...
23 September 2015 | By Victoria White
Turing, the company that increased the price of Daraprim by over 5000%, has said that the price of the drug will be lowered but has not confirmed what the new price will be...
23 September 2015 | By Victoria White
This year’s entries include innovations and new service offerings from across the entire spectrum of the pharmaceutical supply chain...
23 September 2015 | By Victoria White
The Company said that the clinical data from a Phase 1/2a study confirm the very good overall safety profile of the fully human HuCAL antibody...
22 September 2015 | By Victoria White
Zalviso is designed to offer sustained (for up to 72 hours) pain relief for acute moderate-to-severe post-operative pain...
22 September 2015 | By Victoria White
PXS-4728A is a highly selective inhibitor of an enzyme and adhesion protein which reduces inflammation and oxidative stress...
22 September 2015 | By Victoria White
The FDA awards the grants through the Orphan Products Grants Programme to encourage clinical development of treatments for use in rare diseases...
22 September 2015 | By Victoria White
Both Phase 3 studies met their primary endpoints as measured by the proportion of patients receiving tofacitinib in remission at Week 8 compared to patients receiving placebo...
21 September 2015 | By Roche
Roche announced that new Esbriet® (pirfenidone) data analyses in idiopathic pulmonary fibrosis (IPF) will be presented at the European Respiratory Society (ERS) congress in Amsterdam, 26-30 September 2015...
21 September 2015 | By Victoria White
Merck plans to submit new drug applications seeking regulatory approval of bezlotoxumab in the US, EU and Canada in 2015...
21 September 2015 | By Victoria White
The FDA approval is based on the results of three 3-week controlled trials in adults with bipolar I disorder and three 6-week placebo-controlled trials in adults with schizophrenia...
21 September 2015 | By Victoria White
Following news that a British man had been producing the Polio virus for 30 years, experts say high immunisation coverage should keep us covered, but changes to immunisation strategies may be required...
21 September 2015 | By Victoria White
The EC has granted Marketing Authorisation for Intuniv for the treatment of ADHD in children and adolescents for whom stimulants are not suitable...
17 September 2015 | By Black Swan
Market Publishers and Black Swan Analysis signed a partnership agreement for quality market research promotion on the Internet...
17 September 2015 | By Victoria White
The DUAL V trial evaluated the efficacy and safety of Xultophy compared to insulin glargine U100 in adults with type 2 diabetes...
